Post-chemotherapy treated cancer patients frequently report cognitive difficulties. The biology of this phenomenon is poorly understood, with uncertainty about possible direct toxic effects on the brain, secondary effects from systemic inflammation, host factors/genetic predisposition to cognitive complaints, or hormonal changes influencing cognitive function. To elucidate possible mechanisms associated with post-treatment cognitive dysfunction among breast cancer survivors, in 2007 we established a prospective, longitudinal, observational cohort study of early stage breast cancer patients, recruited at the end of initial treatments (primary treatment exposure included surgery, ±radiation, ±chemotherapy), and prior to the initiation of adjuvant endocrine therapy. We assessed cognitive complaints, neuropsychological (NP) test performance, markers of inflammation, and brain imaging at baseline, 6 months and 12 months after enrollment. In this analysis of data from the first 93 patients enrolled in the cohort study, we focus on the relationship of circulating levels of proinflammatory cytokines to cerebral functioning and chemotherapy exposure. Among the proinflammatory cytokines tested (IL-1ra, sTNF-RII, CRP, and IL-6) at baseline, only sTNF-RII was increased among chemotherapy exposed patients, with a significant decline in the year after treatment (p = 0.003). Higher baseline sTNF-RII in chemotherapy patients was significantly associated with increased memory complaints. In chemotherapy exposed patients, the longitudinal decline in sTNF-RII was significantly correlated with fewer memory complaints over 12 months (r = À0.34, p = 0.04). Higher baseline sTNF-RII was also associated with relatively diminished brain metabolism in the inferior frontal cortex (r = À0.55, p = 0.02), as well as relatively increased inferior frontal metabolism after 1 year, in chemotherapy-exposed subjects. These preliminary findings suggest that post-chemotherapy increases in TNF-a may be playing an important role in the manifestations of cognitive complaints in breast cancer survivors.
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Introduction
With the growing number of cancer survivors, there has been increased interest in the risk factors for and mechanisms by which certain post-treatment symptoms occur and persist (Castellon et al., 2004; Ahles and Saykin, 2007; Donovan et al., 2004; Stein et al., 2000; Bower et al., 2000; Bower, 2007 Bower, , 2008 Collado-Hidalgo et al., 2008; Miller et al., 2008) . Cognitive dysfunction after cancer treatments has been among the most feared post-treatment concern in cancer survivors, and this problem has been particularly associated with cranial radiation, intrathecal chemotherapy, as well as systemic chemotherapy and biotherapy (e.g. interleukin-2, interferon-a) (Meyers, 2000 (Meyers, , 2008 Butler et al., 1994; Wefel et al., 2008; Capuron et al., 2004) . Breast cancer patients and survivors have been among the most extensively studied with regard to cognitive dysfunction among adult cancer survivors. Early studies were primarily cross-sectional and conducted in long term survivors (Schagen et al., 1999; van Dam et al., 1998; Ahles et al., 
